Table 3.
Miscellaneous outcomes reported in the included studies
| Study, Year | Outcomes Analyzed | Results |
|---|---|---|
| Bagnis, 1998 (29) | BAP, osteocalcin | Reduction in osteocalcin but not BAP |
| Courbebaisse, 2009 (19) | UCa/Cr, urinary calcium, eGFR | NS change with intervention |
| Chandra, 2008 (24) | BAP, C telopeptide, TRAP 5b | NS change with intervention |
| Dogan, 2008 (25) | Albumin, UCa/Cr, BAP, eGFR | NS change with intervention |
| Blair, 2008 (30) | Albumin, Hb, eKt/V, nPCR, SF 36 | Significant improvement in Hb, nPCR |
| Finn, 2009 (39) | Albumin, eGFR | NS change with intervention |
| Jean, 2009 (33) | Albumin, Hb, eKt/V, nPCR, ESA requirement | NS change with intervention |
| Lopes, 2009 (20) | BAP, urinary calcium, FGF23, | Significant reduction in BAP and increase in Urinary calcium |
| Mathias, 2009 (40) | ESA requirement | NS change with intervention |
| Saab, 2007 (34) | ESA requirement | NS change with intervention |
| Oksa, 2008 (23) | Urinary calcium | NS change with intervention |
| Wissing, 2005 (26) | Urinary calcium | NS change with intervention |
| Zisman, 2007 (37) | eGFR | NS change with intervention |
BAP, bone alkaline phosphatase; UCa/Cr, urinary calcium-to-creatinine ratio; eGFR, estimated GFR; eKtV, estimated KtV; TRAP 5B, tartarate-resistant acid phosphatase isoform 5 b; Hb, hemoglobin; nPCR, protein catabolic rate; SF 36, Standard Form 36 questionnaire; ESA, erythropoietin stimulating agents; NS, not significant; FGF23, fibroblast growth factor-23.